• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Ingevity Corporation

    3/31/25 7:01:43 AM ET
    $NGVT
    Major Chemicals
    Industrials
    Get the next $NGVT alert in real time by email
    DEFA14A 1 ef20046475_defa14a.htm DEFA14A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 14A
     
    Proxy Statement Pursuant to Section 14(a)
    of the Securities Exchange Act of 1934
    (Amendment No.      )

    Filed by the Registrant   ☒

    Filed by a party other than the Registrant   ☐

    Check the appropriate box:
     
    ☐
    Preliminary Proxy Statement

    ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐
    Definitive Proxy Statement

    ☒
    Definitive Additional Materials

    ☐
    Soliciting Material Pursuant to §240.14a-12

    INGEVITY CORPORATION

    (Name of Registrant as Specified In Its Charter)
     

    (Name of Person(s) Filing Proxy Statement, if Other Than The Registrant)
     
    Payment of Filing Fee (Check the appropriate box):
     
    ☒
    No fee required.
    ☐
    Fee paid previously with preliminary materials.
    ☐
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11



    On March 30, 2025, Ingevity Corporation (the “Company”) filed a Current Report on Form 8-K (the “Cooperation Agreement 8-K”) with the Securities and Exchange Commission (the “SEC”) disclosing its entry into a Cooperation Agreement with Vision One Fund, LP and certain of its affiliates. The Company is filing this Form DEFA14A on Schedule 14A to update the Company’s Definitive Proxy Statement (the “Proxy Statement”) filed with the SEC on March 20, 2025 with the information contained in the Cooperation Agreement 8-K. The below information supplements, and should be read in conjunction with, the Proxy Statement.



    Item 1.01
    Entry Into a Material Definitive Agreement.

    Cooperation Agreement

    On March 30, 2025, Ingevity Corporation (the “Company”) entered into a cooperation agreement (the “Cooperation Agreement”) with Vision One Fund, LP and certain of its affiliates (the “Vision One Parties”).

    Pursuant to the Cooperation Agreement, the Company agreed to (i) appoint F. David Segal to the Company’s Board of Directors (the “Board”) within one day of the 2025 annual meeting of stockholders (the “2025 Annual Meeting”), (ii) appoint Mr. Segal to the Audit Committee of the Board and (iii) not increase the size of the Board to more than eleven directors until the earliest date pursuant to which stockholder nominations for director elections are permitted to be delivered pursuant to the Company’s bylaws for the Company’s 2026 annual meeting of stockholders (the “Expiration Date”). The Cooperation Agreement provides that the Company and Vision One parties will cooperate in good faith to select a mutually agreeable replacement director in the event that Mr. Segal ceases to serve as a director before the Expiration Date.

    Pursuant to the Cooperation Agreement, the Vision One Parties agreed to withdraw their nominees for the 2025 Annual Meeting and to abide by certain customary standstill restrictions, mutual non-disparagement provisions, voting commitments, including supporting each director nominated and recommended by the Board for election, and other obligations until the Expiration Date.

    The foregoing description of the Cooperation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Cooperation Agreement, a copy of which is attached as Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on March 30, 2025.



    Get the next $NGVT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NGVT

    DatePrice TargetRatingAnalyst
    2/26/2025$62.00 → $65.00Market Perform → Outperform
    BMO Capital Markets
    8/7/2024$58.00Market Perform → Market Outperform
    CJS Securities
    4/22/2024$52.00 → $62.00Hold → Buy
    Jefferies
    11/6/2023$49.00Market Outperform → Market Perform
    CJS Securities
    10/3/2023$62.00 → $53.00Buy → Hold
    Loop Capital
    8/7/2023$71.00 → $60.00Outperform → Market Perform
    BMO Capital Markets
    7/27/2023$64.00 → $75.00Hold → Buy
    Loop Capital
    5/5/2023$92.00 → $64.00Buy → Hold
    Loop Capital
    More analyst ratings

    $NGVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Blackwell Jean was granted 4,057 shares, increasing direct ownership by 145% to 6,857 units (SEC Form 4)

      4 - Ingevity Corp (0001653477) (Issuer)

      5/5/25 6:42:08 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Director Fernandez-Moreno Luis M was granted 4,057 shares, increasing direct ownership by 8% to 53,105 units (SEC Form 4)

      4 - Ingevity Corp (0001653477) (Issuer)

      5/5/25 6:38:06 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Director Lynch Frederick J was granted 4,057 shares, increasing direct ownership by 18% to 26,359 units (SEC Form 4)

      4 - Ingevity Corp (0001653477) (Issuer)

      5/5/25 6:33:42 PM ET
      $NGVT
      Major Chemicals
      Industrials

    $NGVT
    SEC Filings

    See more
    • SEC Form S-8 filed by Ingevity Corporation

      S-8 - Ingevity Corp (0001653477) (Filer)

      5/7/25 4:16:03 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • SEC Form S-8 POS filed by Ingevity Corporation

      S-8 POS - Ingevity Corp (0001653477) (Filer)

      5/7/25 4:15:57 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • SEC Form 10-Q filed by Ingevity Corporation

      10-Q - Ingevity Corp (0001653477) (Filer)

      5/6/25 4:24:35 PM ET
      $NGVT
      Major Chemicals
      Industrials

    $NGVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ingevity upgraded by BMO Capital Markets with a new price target

      BMO Capital Markets upgraded Ingevity from Market Perform to Outperform and set a new price target of $65.00 from $62.00 previously

      2/26/25 7:15:06 AM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity upgraded by CJS Securities with a new price target

      CJS Securities upgraded Ingevity from Market Perform to Market Outperform and set a new price target of $58.00

      8/7/24 9:18:13 AM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity upgraded by Jefferies with a new price target

      Jefferies upgraded Ingevity from Hold to Buy and set a new price target of $62.00 from $52.00 previously

      4/22/24 7:39:26 AM ET
      $NGVT
      Major Chemicals
      Industrials

    $NGVT
    Financials

    Live finance-specific insights

    See more
    • Ingevity reports first quarter 2025 financial results

      HIGHLIGHTS: Net sales of $284.0 million, down 17% compared to prior year, primarily due to repositioning actions in Performance Chemicals, which included the exit of certain lower-margin end markets Net income of $20.5 million and diluted earnings per share (EPS) of $0.56 reflects before-tax special charges of $20.2 million; adjusted earnings of $36.4 million and diluted adjusted EPS of $0.99 Adjusted EBITDA of $91.3 million increased 23% and adjusted EBITDA margin improved to 32.1% due primarily to the successful execution of repositioning actions in Performance Chemicals and continued strong profitability in Performance Materials Operating cash flow of $25.4 million with free cash

      5/5/25 4:15:00 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity announces dates for first-quarter 2025 earnings release and webcast

      Ingevity Corporation (NYSE:NGVT) announced today that it will release its first-quarter 2025 earnings after the stock market close on Monday, May 5, 2025. The company will host a live webcast on Tuesday, May 6, at 9:00 a.m. (Eastern) to discuss first-quarter 2025 fiscal results. The webcast can be accessed here or on the investors section of Ingevity's website. Participants may also listen to the conference call by dialing 833 470 1428 (inside the U.S.) and entering access code 815699. Callers outside the U.S. can find global dial-in numbers here. For those unable to join the live event, a recording will be available beginning at approximately 2:00 p.m. (Eastern) on May 6, 2025, through M

      4/24/25 9:00:00 AM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity reports fourth quarter and full year 2024 financial results

      Fourth Quarter: Net sales of $298.8 million decreased 20% compared to prior year primarily due to repositioning actions in the Performance Chemicals segment that resulted in the exit of lower-margin end markets Net income of $16.6 million and diluted earnings per share (EPS) of $0.46, including pre-tax restructuring charges of $23.4 million; adjusted earnings of $34.7 million and diluted adjusted EPS of $0.95 Adjusted EBITDA of $80.6 million and adjusted EBITDA margin of 27.0% Operating cash flow of $64.5 million and free cash flow of $39.6 million, which included the second and final $50.0 million installment of a termination fee for a long-term crude tall oil (CTO) supply agreemen

      2/18/25 4:15:00 PM ET
      $NGVT
      Major Chemicals
      Industrials

    $NGVT
    Leadership Updates

    Live Leadership Updates

    See more
    • Ingevity Files Definitive Proxy Statement and Issues Letter to Stockholders

      Board and Management Team Have Taken Significant and Decisive Action to Respond to External Market Challenges Key Transformational Changes Are Driving Strong Financial Results and Stock Price Outperformance Continued Execution of Proven Strategy Positions Ingevity to Unlock Significant Additional Stockholder Value Company Urges Stockholders to Vote "FOR" ONLY Ingevity's Highly Qualified Director Nominees on the WHITE Proxy Card Launches VoteIngevity.com Providing Additional information for Stockholders Ingevity Corporation (NYSE:NGVT) today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connection with its 2025 Annual Meet

      3/20/25 5:34:00 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity announces appointment of David H. Li as president and CEO

      Li brings 25-year+ record of driving successful corporate transformation, long-term growth and stockholder value creation at premier global specialty materials supplier Ingevity Corporation (NYSE:NGVT) today announced that its board of directors has appointed David H. Li as the company's president and CEO, effective as of April 7, 2025, and that he is expected to join the board of directors following the 2025 Annual Meeting. Li succeeds Ingevity board member, Luis Fernandez-Moreno, who has been serving as interim president and CEO since October 2024. Fernandez-Moreno will remain on Ingevity's board. This press release features multimedia. View the full release here: https://www.businesswir

      3/10/25 4:15:00 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity Highlights Significant Momentum on Actions Underway to Drive Improved Performance and Value Creation

      Delivered Record Year in Performance Materials and Strategic Repositioning in Performance Chemicals Is Already Demonstrating Results Business Portfolio Review Is Progressing with Recently Announced Strategic Alternatives Process for Industrial Specialties Product Line and Evaluation of Additional Portfolio and Cost Reduction Actions Ongoing Provides Information About Engagement with Vision One Ingevity Corporation (NYSE:NGVT) today issued the following letter to stockholders in response to the presentation issued by Vision One Management Partners ("Vision One") earlier today: Dear Ingevity Stockholders, The Ingevity Board of Directors and leadership team are committed to taking ag

      2/25/25 4:21:00 PM ET
      $NGVT
      Major Chemicals
      Industrials

    $NGVT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ingevity reports first quarter 2025 financial results

      HIGHLIGHTS: Net sales of $284.0 million, down 17% compared to prior year, primarily due to repositioning actions in Performance Chemicals, which included the exit of certain lower-margin end markets Net income of $20.5 million and diluted earnings per share (EPS) of $0.56 reflects before-tax special charges of $20.2 million; adjusted earnings of $36.4 million and diluted adjusted EPS of $0.99 Adjusted EBITDA of $91.3 million increased 23% and adjusted EBITDA margin improved to 32.1% due primarily to the successful execution of repositioning actions in Performance Chemicals and continued strong profitability in Performance Materials Operating cash flow of $25.4 million with free cash

      5/5/25 4:15:00 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity announces dates for first-quarter 2025 earnings release and webcast

      Ingevity Corporation (NYSE:NGVT) announced today that it will release its first-quarter 2025 earnings after the stock market close on Monday, May 5, 2025. The company will host a live webcast on Tuesday, May 6, at 9:00 a.m. (Eastern) to discuss first-quarter 2025 fiscal results. The webcast can be accessed here or on the investors section of Ingevity's website. Participants may also listen to the conference call by dialing 833 470 1428 (inside the U.S.) and entering access code 815699. Callers outside the U.S. can find global dial-in numbers here. For those unable to join the live event, a recording will be available beginning at approximately 2:00 p.m. (Eastern) on May 6, 2025, through M

      4/24/25 9:00:00 AM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity Files Definitive Proxy Statement and Issues Letter to Stockholders

      Board and Management Team Have Taken Significant and Decisive Action to Respond to External Market Challenges Key Transformational Changes Are Driving Strong Financial Results and Stock Price Outperformance Continued Execution of Proven Strategy Positions Ingevity to Unlock Significant Additional Stockholder Value Company Urges Stockholders to Vote "FOR" ONLY Ingevity's Highly Qualified Director Nominees on the WHITE Proxy Card Launches VoteIngevity.com Providing Additional information for Stockholders Ingevity Corporation (NYSE:NGVT) today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connection with its 2025 Annual Meet

      3/20/25 5:34:00 PM ET
      $NGVT
      Major Chemicals
      Industrials

    $NGVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ingevity Corporation

      SC 13G/A - Ingevity Corp (0001653477) (Subject)

      11/12/24 3:54:24 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Ingevity Corporation

      SC 13G/A - Ingevity Corp (0001653477) (Subject)

      11/4/24 11:52:25 AM ET
      $NGVT
      Major Chemicals
      Industrials
    • SEC Form SC 13D/A filed by Ingevity Corporation (Amendment)

      SC 13D/A - Ingevity Corp (0001653477) (Subject)

      2/28/24 5:30:32 PM ET
      $NGVT
      Major Chemicals
      Industrials